GGrantIndex
← Leaderboards

Nora C Heisterkamp

Children'S Hospital Los Angeles

$7,613,746
Attributed
$8,853,766
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY200517
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

NIH$8,853,766 · 4

By mechanism

R01$7,142,595 · 3
P01$1,711,171 · 1

Top collaborators

Most similar at Children'S Hospital Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Leukemia

Research focus

LeukemiaCellsDrug ResistanceLaboratory MouseIn VitroStromal CellsGenetically Modified AnimalsResearch StudyProtein Tyrosine KinasePharmaceutical PreparationsLeukemia, Lymphocytic, AcuteLeukemic CellMouse ModelAntineoplastic AgentsIn VivoChemotherapyMalignant NeoplasmsOncogenicResistance DevelopmentProteinsRelapseCell TypeGene ExpressionCell Surface

Grant awards (38)

Role of Sialic Acid Modification in ALL Survival and Drug Resistance$284,135
R01 · FY2017 · CA · contact PI
Microenvironment-Leukemia Communication Through Lectins$263,687
R01 · FY2017 · CA · contact PI
Microenvironment-Leukemia Communication Through Lectins$89,230
R01 · FY2017 · CA · contact PI
Microenvironment-Leukemia Communication Through Lectins$336,150
R01 · FY2016 · CA · contact PI
Role of Sialic Acid Modification in ALL Survival and Drug Resistance$266,069
R01 · FY2016 · CA · contact PI
Microenvironment-Leukemia Communication Through Lectins$336,150
R01 · FY2015 · CA · contact PI
Role of Sialic Acid Modification in ALL Survival and Drug Resistance$266,069
R01 · FY2015 · CA · contact PI
Microenvironment-Leukemia Communication Through Lectins$326,066
R01 · FY2014 · CA · contact PI
Role of Sialic Acid Modification in ALL Survival and Drug Resistance$258,087
R01 · FY2014 · CA · contact PI
Microenvironment-Leukemia Communication Through Lectins$336,150
R01 · FY2013 · CA · contact PI
Role of Sialic Acid Modification in ALL Survival and Drug Resistance$266,069
R01 · FY2013 · CA · contact PI
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs$258,678
R01 · FY2011 · CA · contact PI
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs$266,679
R01 · FY2010 · CA · contact PI
Treatment of Bcr/Abl caused leukemias with FTIs$492,085
R01 · FY2009 · CA · contact PI
Genetics$316,557
P01 · FY2009 · HL · contact PI
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs$266,679
R01 · FY2009 · CA · contact PI
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs$266,679
R01 · FY2008 · CA · contact PI
Genetics$114,352
P01 · FY2008 · HL · contact PI
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs$42,525
R01 · FY2008 · CA · contact PI
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs$266,679
R01 · FY2007 · CA · contact PI
Genetics$110,362
P01 · FY2007 · HL · contact PI
Genetics$97,177
P01 · FY2006 · HL · contact PI
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs$247,903
R01 · FY2005 · CA
Genetics$96,617
P01 · FY2005 · HL
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs$247,903
R01 · FY2004 · CA
MOUSE MODEL FOR PH-POSTIVE CML AND ALL$266,206
R01 · FY2003 · CA
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs$247,903
R01 · FY2003 · CA
MOUSE MODEL FOR PH-POSTIVE CML AND ALL$265,270
R01 · FY2002 · CA
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs$247,903
R01 · FY2002 · CA
CORE--TRANSGENIC MOUSE$187,536
P01 · FY2002 · HL
CORE--TRANSGENIC MOUSE$187,536
P01 · FY2002 · HL
TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIs$247,903
R01 · FY2001 · CA
MOUSE MODEL FOR PH-POSTIVE CML AND ALL$234,369
R01 · FY2001 · CA
CORE--TRANSGENIC MOUSE$187,536
P01 · FY2001 · HL
MOUSE MODEL FOR PH-POSTIVE CML AND ALL$15,000
R01 · FY2001 · CA
MOUSE MODEL FOR PH-POSTIVE CML AND ALL$234,369
R01 · FY2000 · CA
CORE--TRANSGENIC MOUSE$225,962
P01 · FY2000 · HL
CORE--TRANSGENIC MOUSE$187,536
P01 · FY2000 · HL